IRVINE, Calif., Nov. 5, 2021 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today announced that a cost-effectiveness analysis comparing transcatheter aortic valve replacement (TAVR) to surgery demonstrated that TAVR with SAPIEN 3 is an economically dominant treatment strategy, offering improved outcomes and reduced cost. This […]
Tag: Edwards Lifesciences
Edwards Lifesciences Reports Third Quarter Results
IRVINE, Calif., Oct. 27, 2021 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2021. Third Quarter Highlights and 2021 Outlook Sales grew 15 percent to $1.3 billion; underlying1 sales grew 14 percent TAVR sales grew 15 percent; underlying 14 […]
Edwards Lifesciences Reports Second Quarter Results
IRVINE, Calif., July 29, 2021 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2021. Second Quarter Highlights and 2021 Outlook Sales rebounded and grew 49 percent to $1.4 billion; underlying1 sales grew 44 percent TAVR sales exceeded expectations […]
Edwards Receives Clearance For Hypotension Prediction Index Software For Noninvasive Acumen IQ Cuff
IRVINE, Calif., June 1, 2021 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today announced that Acumen Hypotension Prediction Index (HPI) software with the Acumen IQ finger cuff has received U.S. Food and Drug Administration clearance. This is the first noninvasive solution that unlocks Acumen HPI […]
Real-World Data Confirm Excellent Results For Bicuspid Patients Treated With Edwards SAPIEN 3 TAVR
At 1 year, outcomes similar to overall cohort of patients IRVINE, Calif., May 18, 2021 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today announced the results of a real-world study comparing outcomes for patients with bicuspid aortic stenosis (AS) who were treated with SAPIEN 3 […]
Clinical Data Updates On Edwards’ Transcatheter Mitral, Tricuspid Programs Presented At EuroPCR
IRVINE, Calif., May 18, 2021 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today announced that clinical results from the company’s transcatheter mitral and tricuspid programs were presented as part of the late-breaking clinical trials at EuroPCR 2021, demonstrating positive outcomes for patients impacted by […]
Edwards RESILIA Tissue Aortic Valve Demonstrates Favorable Safety and Efficacy at Five Years
AUSTIN, Texas, Jan. 31, 2021 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today announced new data from the COMMENCE clinical trial that demonstrate Edwards’ bioprosthetic surgical aortic valve with the company’s novel RESILIA tissue platform show favorable safety and hemodynamic performance through a median […]
Edwards Lifesciences Reports Fourth Quarter Results
IRVINE, Calif., Jan. 27, 2021 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended December 31, 2020. Fourth Quarter Highlights and Outlook Q4 sales increased 1 percent to $1.2 billion; underlying1 sales flat Q4 TAVR sales grew 2 percent; underlying sales […]
Edwards Treats First Patient In U.S. Clinical Trial Evaluating Minimally Invasive Device For Mitral Valve Disease
IRVINE, Calif., Dec. 21, 2020 /PRNewswire/ — Edwards Lifesciences (NYSE: EW), today announced that the first patient has been treated in the RESTORE clinical trial, which will evaluate the safety and effectiveness of the investigational HARPOON Beating Heart Mitral Valve Repair System in the United […]
Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference
IRVINE, Calif., Dec. 10, 2020 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW) will discuss the company’s strategy for longer-term growth, provide an update on its technology pipeline and share its financial guidance today during its annual investor conference. Highlights1 of today’s conference include: Presenting […]